Silicon Laboratories Inc. reported its third-quarter fiscal 2026 financial results on November 10, 2026, covering the three months ended October 3, 2026, disclosing $251 million in revenue and a swing to GAAP profitability compared with the year-ago quarter.

Key Highlights

  • Revenue of $250.892 million: up 22% year-over-year from $205.999 million in the comparable prior-year quarter, according to the filing.
  • Record medical revenue: medical revenue increased 48% sequentially and more than 300% year-over-year, reaching a new quarterly record, the company disclosed.
  • GAAP diluted EPS of $0.26: compared with a loss of $0.30 in the year-ago quarter, per the filing.
  • Non-GAAP diluted EPS of $1.05: up 228% over the comparable period last year, the company reported.
  • Segment breakdown: Industrial and Commercial revenue was $141 million, up 20% year-over-year; Home and Life revenue was $110 million, up 24% year-over-year.
  • Guidance suspended: Silicon Labs disclosed it has suspended providing forward-looking guidance due to the announced pending acquisition by Texas Instruments.

Silicon Labs Third-Quarter 2026 Financial Results: Revenue Growth and Pending Texas Instruments Acquisition

Silicon Laboratories Inc. (NASDAQ:SLAB) reported third-quarter results for the period ended October 3, 2026, with total revenues of $250.892 million, up from $205.999 million in the same quarter of the prior year. GAAP gross profit was $152.578 million, representing a GAAP gross margin of 60.8%, while non-GAAP gross margin was 61.0%, according to the filing. GAAP operating expenses totaled $144.627 million, yielding GAAP operating income of $7.951 million, compared with a GAAP operating loss of $12.342 million in the year-ago period.

On a non-GAAP basis, which excludes stock compensation expense, intangible asset amortization, merger-related costs, and certain other items as described in the company's reconciliation tables, operating expenses were $112.838 million and operating income was $40.199 million, or 16.0% of revenue. The company disclosed that GAAP net income for the quarter was $8.851 million, compared with a GAAP net loss of $9.936 million in the third quarter of 2025. For the nine months ended October 3, 2026, the filing reported a GAAP net loss of $17.638 million, compared with a net loss of $62.223 million in the comparable prior-year period.

The company disclosed that distributor inventory declined further to what it described as "a multi-year low" and that end customer inventory was "near record lows" during the quarter. The filing stated that bookings "imply a healthy demand environment." Regarding the pending acquisition, the company noted that "due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance." The filing contains forward-looking statements that are, according to the company's cautionary language, subject to various risks and uncertainties that could cause actual results to differ materially.

What Was Disclosed

Silicon Labs filed its third-quarter 2026 earnings disclosure covering the period ended October 3, 2026, reporting revenue of $250.892 million, record medical revenue, GAAP diluted EPS of $0.26, non-GAAP diluted EPS of $1.05, and the suspension of forward-looking guidance amid a pending acquisition by Texas Instruments.